This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

J. Marion Bryant, MD; Lucian Fletcher, Jr., MD; Natalio Schvartz, MD; Harrison Fertig, MD; Richard B. F. Quan, MD

JAMA. 1965;193(12):1021-1026.

Abstract
Currently, neurogenic blockade is used as a supplement to sulfonamide-diuretics (with or without reserpine) when optimal antihypertensive control is not obtained with these drugs alone. Although the use of neurogenic blocking agents preceded that of sulfonamide-diuretics by ten years, the latter have become first in therapeutic choice.

A combination of chlorthalidone and reserpine produced normotension in 58 of 100 ambulatory outpatients with moderate to severe essential hypertension. Twentytwo of 42 subjects with residual hypertension became normotensive when chlorthalidone-reserpine therapy was augmented with a postganglionic sympathetic blocking agent (debrisoquin sulfate).

In the authors' opinion neurogenic blocking agents, or other potent antihypertensive drugs as adjuncts to sulfonamide-diuretics, are indicated in approximately 40% of patients with moderate or severe essential hypertension. Debrisoquin appears to be more practical, as a supplementary antihypertensive drug, than older related blocking agents.

Author Affiliations
From the Department of Medicine, New York University Medical Center, and the New York University Medical Divisions, Bellevue Hospital, New York.

Footnotes
Reprint requests to New York University School of Medicine, 550 First Ave, New York 10016 (Dr. Bryant).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Debrisoquin in the Therapy of Hypertension
Orgain and Kern
Arch Intern Med 1970;125:255-257.
ABSTRACT